Introduction
Fibromyalgia syndrome (FMS) is a clinically defined chronic condition characterized by chronic widespread pain, sleep disturbances, cognitive dysfunction and fatigue (Wolfe et al., 2011) . Patients often report high disability levels and negative mood (H€ auser et al., 2015a) . Psychological factors play a major role in the predisposition, triggering and perpetuation of FMS ( € Uc ßeyler et al., 2017) . Therefore, psychological therapies may help to reduce key symptoms and improve daily functioning.
Cognitive behavioural therapies (CBTs) are the dominant contemporary psychological treatments for chronic pain. CBTs are used to manage chronic pain by attempting to change negative thoughts about pain, and introduce behaviour modification, to improve function and cope with pain. CBTs are the 'gold-standard' psychological treatment for FM patients according to the Division 12 of the American Psychological Association (Society of Clinical Psychology, 2017) . However, there is no universally accepted definition of which techniques constitute CBT (Morley, 2011) . Within the label 'CBTs', 'classical', operant therapies, psychoeducation, different types of cognitive behavioural therapies and acceptance-based therapies are included (Kaiser and Nilges, 2015) . Acceptance and commitment therapy (ACT) received strong research support for chronic/ persistent pain by the Division 12 of the American Psychological Association (Society of Clinical Psychology, 2017) .
Despite a large amount of research and recommendations for the management of FMS by recent evidence-based guidelines (K€ ollner et al.,2017; MacFarlane et al., 2017) some major questions on the importance of CBTs in FMS are not definitely answered:
(1) Efficacy: The magnitude of the effects sizes of CBTs on the key symptoms of FMS and on disability ranged between small and moderate in different reviews (Thieme and Gracely, 2009; Glombiewski et al., 2010; Bernardy et al., 2013) . Recent systematic reviews did not include acceptance-based studies (Thieme and Gracely, 2009; Glombiewski et al., 2010; Bernardy et al., 2013) . If one type of CBTs is superior in terms of efficacy in FMS has not been studied to our knowledge. (2) Responder analysis: Recent standards for systematic reviews with meta-analysis of RCTs in chronic pain require the reports of responders, e.g. the number of patients with a substantial reduction in pain or of health-related quality of life (Moore et al., 2010) . This recommendation is based on individual patient data analysis which demonstrated that pain responses in chronic pain trials are not normally distributed but have a bimodal distribution. Consequently, the 'average' pain score represents a result that few patients experience. However, CBT trials in FMS mostly reported average scores in the past . (3) Optimal treatment dose: One systematic review found that higher treatment dose was associated with better outcome (Glombiewski et al., 2010) . Taking into consideration the limited availability of CBTs in many countries of the world, it is important to know, if very shortterm CBTs are as effective as short-and longterm CBTs. (4) Safety: Assessment of serious adverse events has been neglected by psychological trials in the past (Kashikar-Zuck, 2010) . If the assessment and reporting of adverse events in CBTs trials of FMS has improved in the last years, has not been studied (5) Comparison of CBTs with other guideline-recommended therapies: There is still a paucity of studies which directly compare guideline recommended drug therapies and psychological therapies (N€ uesch et al., 2013) . These open questions given, we updated our systematic review on the efficacy, acceptability and safety of CBTs compared to control groups in FMS patients of any age at the end of treatment and at long-term (at least 6 months) follow-up with special emphasis on analysis of responders and of safety, subgroup analysis (type of CBTs, duration of treatment) and comparisons with recommended drug therapies.
Methods
The review was performed according to the PRISMA-statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Moher et al., 2009 ) and the recommendations of the Cochrane Collaboration (Higgins and Green, 2011) .
Protocol
Methods of analysis and inclusion criteria were specified in advance (DOI number https://doi.org/10. 1002/14651858.CD009796.pub2 .
Criteria for considering studies for this review
2.1.1.1 Types of participants. We included patients of any age with a clinical diagnosis of FMS by any published, recognized and standardized criteria (Smythe, 1981; Yunus et al., 1981; Wolfe et al., 1990 Wolfe et al., , 2010 Wolfe et al., , 2011 .
2.1.1.2 Types of interventions. Due to the broad variety of behavioural and cognitive behavioural psychological therapy techniques, we use in the following context the term 'cognitive behavioural therapies' (CBTs). For the purposes of this review we considered the following techniques (Jensen, 2011) .
(1) Operant therapy, which requires techniques to increase activity, the inclusion of significant others to reduce reinforcement of pain behaviours, and the reduction in pain-contingent medication (Fordyce, 1976) . (2) Traditional cognitive behavioural therapy (CBT), which requires monitoring of one's own thoughts, feelings and behaviours with respect to the target symptom (e.g. by a symptom diary) and the promotion of alternative ways of coping with the target symptom (also labelled as problem-solving techniques, self management, coping skills), through methods such as activity participation and skill-building or practice opportunities (Williams et al., 2012) . (3) Self management education programmes, which require information on the clinical picture of FMS, cognitive and behavioural skills mastery to manage pain and limitations of daily activities, and modelling as supplied by the facilitators to target cognitive, behavioural and emotional change (Warsi et al., 2003) . (4) Acceptance-based CBTs, which include acceptance and commitment therapy, or contextual CBT or mindfulness-based cognitive therapy. All these therapies use acceptance techniques (e.g. mindfulness meditation training) to facilitate a separation between 'self' and one's thoughts, feelings and pain experience, and encourage patients to base their actions on their most important values as opposed to their immediate feelings, thoughts and pain (Veehof et al., 2016) . We judged a psychological treatment to be credible if it was based on an extant CBT model or framework and its delivery was from, or supervised by, a healthcare professional trained in an extant CBT model or framework. In addition, the delivery by a lay leader was accepted in the case of self management education programs. We included trials comparing face-to-face or telephone-based (voice tovoice) CBTs as an active treatment of primary interest with controls.
We excluded the following types of psychological therapies from this review.
• Studies with mindfulness-based stress reduction • Studies with education only: any combination of information on the symptoms and management of FMS, discussion or emotional support without skills mastery and modelling as supplied by the facilitators.
• Studies in which CBTs were combined with any other defined active therapy (physical exercise, physical therapy or drug therapy with defined extent and intensity (so-called multicomponent or multidisciplinary therapy) (Kaiser et al., 2017 ), because it is not possible to separate the effects of CBTs from these other active therapies.
• Studies with CBTs delivered by Internet without any personal contact (e.g. email, telephone) with a healthcare professional trained in an extant CBT model or framework.
2.1.1.3 Types of studies. We accepted an attention control, waiting list control, treatment as usual, no therapy and any other active therapy as controls. In case of multiple control groups, we preferred the following order: attention control, waiting list control, treatment as usual, no therapy, any other active therapy. We included studies with a parallel and, cross-over design. We included studies with a cross-over design where (1) separate data from the two periods were reported, or (2) data were presented that excluded a statistically significant carry-over effect, or (3) statistical adjustments were carried out in case of a significant carry-over effect. Trials should report at least one of the outcomes of efficacy as defined below and of acceptability or safety as defined below.
We included studies which were available as a full publication or a report of the RCT in a peerreviewed journal or in a database, had a design that placed a CBT as an active treatment of primary interest; had a credible CBT content; had 10 or more participants in each treatment arm for analysis at the end of treatment; had a study duration of 2 weeks and more.
2.1.1.4 Types of outcome measures. When there was more than one measure for an outcome we gave preference to the measure that was most frequently used. Also, when there was a choice between singleitem and multi-item self report tools, we chose multi-item tools on the basis of inferred increased reliability (Williams et al., 2012) .
We analysed outcome measures at final treatment (end of treatment) and at long-term (at least 6 months) follow-up. Follow-ups <6 months were not considered for the analysis of long-term followup. If more than one follow-up after 6 months had been conducted, the results of the final follow-up visit were extracted for analysis. The search strategy for MEDLINE is outlined in Supporting Information Method S1.
Searching other resources
We searched http://www.clinicaltrials.gov (website of the US National Institutes of Health) for ongoing trials. We searched bibliographies from retrieved relevant articles. We contacted content experts for further possible studies. Our search included all languages.
Measures of treatment effect
The effect measures of choice were risk differences (RD) for dichotomous data and standardized mean differences (SMD) for continuous data (method inverse variance). We used a random-effect model because we assumed clinical heterogeneity was found. Uncertainty was expressed using 95% confidence intervals (CIs). Number needed to treat for an additional benefit (NNTBs) was calculated as the reciprocal of the absolute risk reduction (ARR). For unwanted effects, the NNTB becomes the number needed to treat for an additional harm (NNTH) and is calculated in the same manner. For dichotomous data, we calculated risk differences (RDs). The threshold for 'clinically relevant benefit' or 'clinically relevant harm' was set for categorical variables by an absolute risk reduction or increase ≥10% corresponding a NNTB or NNTH of ≤10 (Moore et al., 2008 ).
Cohen's categories were used to evaluate the magnitude of the effect size of continuous data, calculated by SMD, with values for Hedges' g as follows: 0.2-0.5 equating to a small effect size, 0.5-0.8 equating to a medium effect size, and more than 0.8 equating to a large effect size (Cohen, 1988) . We considered values of g less than 0.2 to equate to a 'not substantial' effect size (H€ auser et al., 2015b) . The threshold 'clinically relevant benefit' was set for continuous variables by an effect size of more than 0.2 (Fayers and Hays, 2014) .
Data collection and analysis

Selection of studies
Two review authors (KB, WH) independently scrutinized all the titles and abstracts and selected studies based on inclusion and exclusion criteria.
form (KB, WH). The classification of the CBT delivered by the studies into self-management, traditional CBT, operant therapy and acceptance-based CBTs was rated independently by two authors (KB, WH) based on the details of therapy as reported by the authors and on the classification of CBTs as outlined in TYPES OF INTERVENTION. Reported treatment quality was rated independently by two authors (KB, WH). We resolved disagreements by discussion, if necessary a third review author (PW) was consulted. One author (WH) entered data into Review Manager (RevMan) 5.3 (RevMan, 2014) , and a second author (KB) validated the entries.
Assessment of risk of bias in included studies
Two review authors (KB, WH) independently assessed the risk of bias of each included trial. Disagreements were resolved by discussion and consensus, otherwise a third review author (PW) acted as arbiter. We assessed the following risks of bias for each study in accordance with methods recommended by The Cochrane Collaboration (Higgins and Green, 2011) . We excluded the option of 'blinding participants and personnel' because neither therapists nor patients can be blinded to whether they deliver or receive treatment (Williams et al., 2012) . We did not consider small sample size bias because this approach would disadvantage trials with psychological therapies with no or public funding (allowing only small to moderate sample sizes) against drug trials sponsored by the manufacturers of the drugs.
The details of the assessment of the risks of bias are outlined in Supporting Information Methods S2.
We defined studies with 0-2 unclear or high risks of bias to be high-quality studies, with 3-4 unclear or high risks of bias to be moderate quality studies, and with 5-6 unclear or high risks of bias to be lowquality studies (H€ auser et al., 2015b) .
Assessment of quality of treatment
We assessed the quality of the treatment using five criteria (treatment content and setting, treatment duration, manualization of the treatment, adherence of the therapist to the manual, therapist training and client engagement) on a quality rating scale designed specifically for application to psychological treatment studies in pain. For client engagement we required that engagement of patients was sought by checks if homework were made. The total score ranges from 0 to 9 (Yates et al., 2005) . We considered scores 0-2 to indicate poor quality, scores 3-5 average and scores 6-9 excellent treatment quality .
Unit of analysis issues
See Supporting Information Methods S3.
Dealing with missing data
Assessment of heterogeneity
Assessment of publication bias
Grading of evidence
See Supporting Information Methods S3 and Data S2.
Results
Search
The updated search produced 561 hits. We excluded two studies because CBTs were delivered by Internet without any contact with a psychotherapist (Williams et al., 2010; Menga et al., 2014) . One of these studies was included in the first version of the review (Williams et al., 2010) . We included seven new studies (Williams et al., 2002; Parra-Delgado and Latorre-Postigo, 2013; Wicksell et al., 2013; Luciano et al., 2014; Mart ınez et al., 2014; Garcia-Palacios et al., 2015; Karlsson et al., 2015) .One study (Williams et al., 2002) was not included in the first version of this review. These studies added 546 new participants. We included 22 studies from the first version of the review (Burckhardt et al., 1994; Vlaeyen et al., 1996; Wigers et al., 1996; Nicassio et al., 1997; Oliver et al., 2001; King et al., 2002; Soares and Grossi, 2002; Williams et al., 2002; Thieme et al., 2003; Redondo et al., 2004; Edinger et al., 2005; Kashikar-Zuck et al., 2005; Thieme et al., 2006; Rooks et al., 2007; Castel et al., 2009 Castel et al., , 2012 Ang et al., 2010; Alda et al., 2011; Luciano et al., 2011; Kashikar-Zuck et al., 2012; Woolfolk et al., 2012; Bernardy et al., 2013) . In sum, 29 studies with 31 study arms were included into the qualitative and quantitative analysis (see Fig. 1 ).
Included studies
The main characteristics of the studies are summarized in Table 1, for details see Supporting Information  Table S1 .
Settings
Eighteen studies were conducted in Europe (Burckhardt et al., 1994; Vlaeyen et al., 1996; Wigers et al., 1996; Soares and Grossi, 2002; Thieme et al., 2003 Thieme et al., , 2006 Redondo et al., 2004; Castel et al., 2009 Castel et al., , 2012 Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Mir o et al., 2011; Parra-Delgado and Latorre-Postigo, 2013; Wicksell et al., 2013; Mart ınez et al., 2014; Garcia-Palacios et al., 2015; Karlsson et al., 2015) , of which 10 were conducted in Spain (Redondo et al., 2004; Castel et al., 2009 Castel et al., , 2012 Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Mir o et al., 2011; ParraDelgado and Latorre-Postigo, 2013; Mart ınez et al., 2014; Garcia-Palacios et al., 2015) , five in Scandinavian countries (Burckhardt et al., 1994; Wigers et al., 1996; Soares and Grossi, 2002; Wicksell et al., 2013; Karlsson et al., 2015) , two studies in Germany (Thieme et al., 2003 (Thieme et al., , 2006 and one study in the Netherlands (Vlaeyen et al., 1996) . Ten studies were conducted in North America (USA) (Nicassio et al., 1997; Oliver et al., 2001; King et al., 2002; Williams et al., 2002; Edinger et al., 2005; Kashikar-Zuck et al., 2005 Rooks et al., 2007; Ang et al., 2010; Woolfolk et al., 2012) and one in South America (Brazil) (Falcao et al., 2008) . All studies but one (Thieme et al., 2003) were outpatient-based. Most studies reported the setting in which CBTs were delivered: four studies in primary care settings (Rooks , 2007; Alda et al., 2011; Luciano et al., 2011; Karlsson et al., 2015) , by six studies in rheumatology clinics (Burckhardt et al., 1994; Thieme et al., 2003; Redondo et al., 2004; Kashikar-Zuck et al., 2005 Woolfolk et al., 2012) by two studies each in pain clinics (Castel et al., 2009 (Castel et al., , 2012 , psychology departments (Thieme et al., 2006; Mart ınez et al., 2014) and rehabilitation clinics (Vlaeyen et al., 1996; King et al., 2002) and by one study in the home of the patients (Ang et al., 2010) . All studies except six (Oliver et al., 2001; Rooks et al., 2007; Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Kashikar-Zuck et al., 2012) were single-centre studies.
Types of CBTs
Twenty-three studies provided traditional CBT (Burckhardt et al., 1994; Vlaeyen et al., 1996; Wigers et al., 1996; Nicassio et al., 1997; King et al., 2002; Soares and Grossi, 2002; Williams et al., 2002; Redondo et al., 2004; Edinger et al., 2005; Kashikar-Zuck et al., 2005; Thieme et al., 2006; Falcao et al., 2008; Castel et al., 2009 Castel et al., , 2012 Ang et al., 2010; Alda et al., 2011; Luciano et al., 2011; Mir o et al., 2011; Kashikar-Zuck et al., 2012; Woolfolk et al., 2012; Mart ınez et al., 2014; Garcia-Palacios et al., 2015; Karlsson et al., 2015) , three studies offered acceptance/mindfulness-based therapy (Parra-Delgado and Latorre-Postigo, 2013; Wicksell et al., 2013; Luciano et al., 2014) and two studies each provided self management education (Oliver et al., 2001; Rooks et al., 2007) and operant therapy (Thieme et al., 2003 (Thieme et al., , 2006 . All studies were conducted by live face-toface contact except one study which was delivered by telephone (voice-to-voice) (Ang et al., 2010) . CBTs were delivered by all studies in groups only except three studies which combined individual and group sessions (Soares and Grossi, 2002; KashikarZuck et al., 2005; Garcia-Palacios et al., 2015) and one study with single person therapy (Kashikar-Zuck et al., 2012).
Study design
One study used a cross-over design (Kashikar-Zuck et al., 2005) , the remaining studies used a parallel design.
The median duration of all CBTs was 10 (3-54) weeks. The median number of sessions was 10 (6-60) and the median total hours was 18 (3-102) h. One study did not report the number and duration of sessions (Woolfolk et al., 2012) . Only one study had a total treatment time <5 h (Ang et al., 2010) and seven studies had a treatment time of >25 h (Wigers et al., 1996; Soares and Grossi, 2002; Thieme et al., 2003; Thieme et al., 2006; Falcao et al., 2008; Castel et al., 2012; Karlsson et al., 2015) . The remaining studies had a treatment time between 5 and 25 h. Fourteen studies reported on average attendance rates of participants (Wigers et al., 1996; Oliver et al., 2001; King et al., 2002; Redondo et al., 2004; Thieme et al., 2006; Rooks et al., 2007; Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Mir o et al., 2011; Castel et al., 2012; Parra-Delgado and Latorre-Postigo, 2013; Mart ınez et al., 2014; Karlsson et al., 2015) . The median of attended CBTs sessions was 77% (range 42-93%). The median of follow-ups which were performed by 21 of eight studies was 6 (3-48) months. Eighteen studies performed follow-ups at equal to or greater than 6 months (Burckhardt et al., 1994; Vlaeyen et al., 1996; Wigers et al., 1996; Nicassio et al., 1997; Soares and Grossi, 2002; Williams et al., 2002; Thieme et al., 2003; Redondo et al., 2004; Edinger et al., 2005; Thieme et al., 2006; Rooks et al., 2007; Alda et al., 2011; Castel et al., 2012; KashikarZuck et al., 2012; Woolfolk et al., 2012; Luciano et al., 2014; Mart ınez et al., 2014) . The follow-up data of Luciano et al., 2011 were reported in Luciano et al., 2013. 
Controls
For comparisons of this review, the following control groups were used: five studies compared with waiting list controls (Burckhardt et al., 1994; King et al., 2002; Wicksell et al., 2013; Luciano et al., 2014; Karlsson et al., 2015) , five studies with attention controls (Vlaeyen et al., 1996; Nicassio et al., 1997; Soares and Grossi, 2002; Thieme et al., 2006; Mir o et al., 2011; Mart ınez et al., 2014) , six studies with active non-pharmacological controls (Thieme et al., 2003; Redondo et al., 2004; Kashikar-Zuck et al., 2005; Rooks et al., 2007; Kashikar-Zuck et al., 2012) , and the remaining studies compared CBTs to treatment as usual. In addition, we added a comparison of two studies which compared to recommended pharmacological therapy (pregabalin and -in case of depressive disorder -duloxetine (Alda et al., 2011; Luciano et al., 2014) .
Participants
We included a total of 1236 participants in treatment groups and 1246 participants in control groups in the analysis. The median number of participants in CBTs groups was 32 (14-207), in controls 30 . Participants were referred and recruited from primary care physicians (Burckhardt et al., 1994; Nicassio et al., 1997; Soares and Grossi, 2002; Redondo et al., 2004; Rooks et al., 2007; Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Wicksell et al., 2013) , from medical/rheumatology departments (Vlaeyen et al., 1996; Nicassio et al., 1997; King et al., 2002; Williams et al., 2002; Thieme et al., 2003; Kashikar-Zuck et al., 2005; Falcao et al., 2008; Mir o et al., 2011; Kashikar-Zuck et al., 2012; Mart ınez et al., 2014) , from self-help organizations (Wigers et al., 1996; Parra-Delgado and LatorrePostigo, 2013) , by media advertisement (Edinger et al., 2005; Rooks et al., 2007; Karlsson et al., 2015) and by health maintenance organisations (Oliver et al., 2001) . The median percentage of women in CBTs groups was 100% (89-100%). Fifteen studies included only women (Burckhardt et al., 1994; King et al., 2002; Soares and Grossi, 2002; Thieme et al., 2003; Redondo et al., 2004; Kashikar-Zuck et al., 2005; Thieme et al., 2006; Falcao et al., 2008; Ang et al., 2010; Mir o et al., 2011; Parra-Delgado and Latorre-Postigo, 2013; Wicksell et al., 2013; Mart ınez et al., 2014; Garcia-Palacios et al., 2015; Karlsson et al., 2015) . The median of the mean age was 47.4 (15.2-55.4) years. Two studies included only children and adolescents (Kashikar-Zuck et al., 2005; Kashikar-Zuck et al., 2012) ; the other studies included only adults. The median percentage of Caucasians was 93% (79-100%). The percentage of Caucasians in the whole sample was probably high because most European studies did not report ethnicity of the patients included. The studies used different criteria of disease duration. Therefore, we did not calculate median values. Overall, the studies included patients with a long disease duration (more than five years) except in three studies (Soares and Grossi, 2002; Falcao et al., 2008; Mir o et al., 2011) which reported a disease duration of <5 years. Disease duration in children and adolescents was reported to be 3 years in one study (Kashikar-Zuck et al., 2012) .
Diagnosis of FMS
FMS was diagnosed in the two studies with children and adolescents (Kashikar-Zuck et al., 2005; Kashikar-Zuck et al., 2012) according to the Yunus criteria (Yunus et al., 1981) . Of the studies with adults, one study (Wigers et al., 1996) used the Smythe criteria (Smythe, 1981) . The remaining studies used the American College of Rheumatology (ACR) 1990 classification criteria (Wolfe et al., 1990) for diagnosis.
Exclusion of anxiety or depressive disorder
Only five studies reported on a (semi-) structured psychiatric interview (Alda et al., 2011; KashikarZuck et al., 2012; Wicksell et al., 2013; Luciano et al., 2014; Garcia-Palacios et al., 2015) . Only two studies reported the percentage of participants with anxiety and depressive disorders. Forty-seven per cent of participants in the CBTs group of Alda et al., 2011 met the criteria of a major depression. Ninety per cent of participants of the CBT group of Garcia- Palacios et al., 2015 had a history of mood or anxiety disorders. Sixteen studies included patients with depressive or anxiety disorders, or both (Burckhardt et al., 1994; Wigers et al., 1996; Nicassio et al., 1997; King et al., 2002; Williams et al., 2002; Thieme et al., 2006; Castel et al., 2009 Castel et al., , 2012 Ang et al., 2010; Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Parra-Delgado and Latorre-Postigo, 2013; Garcia-Palacios et al., 2015; Karlsson et al., 2015) .
Reported treatment quality
Three studies had a low (Vlaeyen et al., 1996; Nicassio et al., 1997; Castel et al., 2009 ), 14 studies had a moderate (Burckhardt et al., 1994; Wigers et al., 1996; Oliver et al., 2001; King et al., 2002; Soares and Grossi, 2002; Williams et al., 2002; Thieme et al., 2003; Redondo et al., 2004; Edinger et al., 2005; Rooks et al., 2007; Falcao et al., 2008; Luciano et al., 2011; Woolfolk et al., 2012; Garcia-Palacios et al., 2015) and 12 studies had a high reported treatment quality ( Table S2 ).
Funding and conflicts of interest
Nineteen studies reported public funding (Burckhardt et al., 1994; Vlaeyen et al., 1996; Wigers et al., 1996; Nicassio et al., 1997; Oliver et al., 2001; King et al., 2002; Williams et al., 2002; Kashikar-Zuck et al., 2005; Thieme et al., 2006; Rooks et al., 2007; Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Mir o et al., 2011; Kashikar-Zuck et al., 2012; Parra-Delgado and Latorre-Postigo, 2013; Mart ınez et al., 2014; GarciaPalacios et al., 2015; Karlsson et al., 2015) . Only seven studies reported on conflicts of interest, of which four studies reported no conflicts of interest (Alda et al., 2011; Castel et al., 2012; Wicksell et al., 2013; Luciano et al., 2014) and three studies reported honoraria of some authors by pharmaceutical companies (Edinger et al., 2005; Ang et al., 2010; Kashikar-Zuck et al., 2012) .
Risk of bias in included studies
Risk of bias could not be properly assessed in all studies except one (Mir o et al., 2011) due to incomplete method reporting. Most of the studies reviewed were published prior to the standardization of RCT reporting, established by the CONSORT statement (Schulz et al., 2010) . According to the predefined categories five studies were high-quality studies (low risk of bias overall) (Alda et al., 2011; Luciano et al., 2011 Luciano et al., , 2014 Kashikar-Zuck et al., 2012; Karlsson et al., 2015) , 11 studies were moderate quality studies (unclear risk of bias overall) (King et Fig. 2 for risk of bias summary and graph).
Effects of intervention
CBTs versus controls (waiting list, treatment as usual, attention controls and active nonpharmacological therapies) at the end of treatment
3.4.1.1 Primary outcomes. Pain relief of 50% or greater: No study reported this outcome. The numbers were calculated by an imputation method. We entered 22 studies with 1498 participants into an analysis of pain relief of 50% or greater. CBTs were statistically significantly superior to controls (p-value 0.0003). One hundred and five out of 789 (13.3%) participants in CBTs groups and 63 out of 709 (8.9%) in control groups reported pain relief of 50% or greater. RD was 0.05 (95% CI 0.02-0.07). NNTB was 20 (95% CI 16-50). According to the predefined categories there was no clinically relevant benefit by CBTs. The quality of evidence was high.
Improvement of health-related quality of life of 20% or greater: Only one study reported this outcome (Luciano et al., 2014) . The numbers of the remaining studies were calculated by an imputation method. We entered 15 studies with 1316 participants into an analysis of improvement of healthrelated quality of life of 20% or greater. CBTs were statistically significantly superior to controls (pvalue 0.04). Two hundred and ninety-three out of 662 (44.3%) participants in CBTs groups and 206 out of 654 (31.5%) participants in control groups reported improvement of health-related quality of life of 20% or greater. RD was 0.13 (95% CI 0.00-0.26). NNTB was 8 (95% CI 4-100). According to the predefined categories there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency. Negative mood: We entered 24 studies with 1877 participants into an analysis of reduction in negative mood. CBTs were statistically significantly superior to controls (p-value < 0.0001). SMD was À0.43 (95% CI À0.62 to À0.24). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was high. Disability: We entered 19 studies with 1324 participants into an analysis of reduction of disability. CBTs were statistically significantly superior to controls (p-value 0.007). SMD was À0.30 (95% CI À0.52 to À0.08). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was high. Fatigue: We entered 12 studies with 899 participants into an analysis of the reduction in fatigue. CBTs were statistically significant superior to controls (p-value 0.02). SMD was À0.27 (95% CI À0.50 to À0.03). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was high. Acceptability: We entered 27 studies with 2291 participants into an analysis of acceptability. There was no statistically significant difference between CBTs and controls (p-value 0.45). One hundred and eighty-two out of 1218 (14.9%) participants in CBTs groups and 138 out of 1073 (12.9%) in the control group dropped out of the study due to any reason. RD was 0.01 (95% CI À0.02 to 0.05). The quality of evidence was high. Safety: We entered four studies with 445 participants into an analysis of safety. There was no statistically significant difference between CBTs and controls (p-value 0.27). In five out of 220 (2.3%) participants in CBTs groups and 0 out of 225 (0%) in control groups a serious adverse event was noted. RD was 0.01 (95% CI À0.01 to 0.04). The quality of evidence was moderate downgraded by one level due to low event rate.
3.4.1.2 Secondary outcomes. Pain relief of 30% or greater: Only one study (Castel et al., 2012) reported this outcome. The numbers of the remaining studies were calculated by an imputation method. We . According to the predefined categories there was no clinically relevant benefit by CBTs. The quality of evidence was high.
Mean pain intensity: We entered 26 studies with 1678 participants into an analysis of reduction in mean pain intensity. CBTs were statistically significant superior to controls (p-value 0.003). SMD was À0.28 (95% CI À0.47 to À0.10). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency.
Coping with pain: We entered 14 studies with 1250 participants into an analysis of improved coping with pain. CBTs were statistically significant superior to controls (p-value 0.0002). SMD was À0.56 (95% CI À0.86 to À0.26). According to the predefined categories, the effect size was moderate and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency.
Sleep problems: We entered eight studies with 363 participants into an analysis of reduction in sleep problems. CBTs were statistically significant superior to controls (p-value 0.02). SMD was À0.50 (95% CI À0.92 to À0.07). According to the predefined categories, the effect size was moderate and there was a clinically relevant benefit by CBTs. The quality of evidence was high.
For Forest Plots see Supporting Information Fig. S1 .
CBTs versus controls (waiting list, treatment
as usual, attention controls and active nonpharmacological therapies) at long-term follow-up 3.4.2.1 Primary outcomes. Pain relief of 50% or greater: No study reported this outcome. The numbers were calculated by an imputation method. We entered 13 studies with 1088 participants into an analysis of pain relief of 50% or greater. CBTs were statistically significant superior to controls (p-value < 0.0001). Eighty seven out of 576 (15.1%) participants in CBTs groups and 32 out of 512 (6.3%) in control groups reported pain relief of 50% or greater. RD was 0.07 (95% CI 0.04-0.10). NNTB was 14 (95% CI 10-25). According to the predefined categories there was no clinically relevant benefit by CBTs. The quality of evidence was high.
Improvement of health-related quality of life of 20% or greater: One study reported this outcome (Luciano et al., 2014) . The numbers of the remaining studies were calculated by an imputation method. We entered seven studies with 631 participants into an analysis of improvement of healthrelated quality of life of 20% or greater. There was no statistically significant difference between CBTs and controls (p-value 0.08). One hundred and fiftyseven of 317 (49.5%) participants in CBTs groups and 84 out of 314 (26.7%) participants in control groups reported an improvement of health-related quality of life of 20% or greater. RD was 0.19 (95% CI À0.03 to 0.40). The quality of evidence was downgraded by one level to moderate because of inconsistency.
Negative mood: We entered 15 studies with 1159 participants into an analysis of reduction in negative mood reduction. CBTs were statistically significantly superior to controls (p-value 0.0008). SMD was À0.48 (95% CI À0.77 to À0.20). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency. Disability: We entered 12 studies with 998 participants into an analysis of reduction in disability. CBTs were statistically significant superior to controls (p-value 0.0001). SMD was À0.53 (95% CI À0.80 to À0.26). According to the predefined categories, the effect size was moderate and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency.
Fatigue: We entered eight studies with 692 participants into an analysis of reduction in fatigue. CBTs were statistically significant superior to controls (p-value 0.0005). SMD was À0.42 (95% CI À0.65 to À0.18). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was high.
3.4.2.2 Secondary outcomes. Pain relief of 30% or greater: One study reported this outcome (Castel et al., 2012) . The numbers of the remaining studies were calculated by an imputation method. We entered 13 studies with 1099 participants into an analysis of pain relief of 30% or greater. CBTs were statistically significant superior to controls (p-value < 0.0001). Two hundred and one out of 587 (34.2%) participants in CBTs groups and 105 out of 512 (20.5%) in control groups reported pain relief of 30% or greater. RD was 0.14 (95% CI 0.08-0.21). NNTB was 7 (95% CI 5-12). According to the predefined categories there was a clinically relevant benefit by CBTs. The quality of evidence was high.
Mean pain intensity: We entered 17 studies with 1272 participants into an analysis of reduction in mean pain. CBTs were statistically significant superior to controls (p-value < 0.0001). SMD was À0.43 (95% CI À0.63 to À0.24). According to the predefined categories, the effect size was small and there was a clinically relevant benefit by CBTs. The quality of evidence was high.
Coping with pain: We entered 11 studies with 772 participants into an analysis of improved coping with pain. CBTs were statistically significant superior to controls (p-value 0.0003). SMD was À0.81 (95% CI À1.25 to À0.37). According to the predefined categories, the effect size was large and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency.
Sleep problems: We entered eight studies with 425 participants into an analysis of reduction in sleep problems. CBTs were statistically significant superior to controls (p-value 0.04). SMD was À0.60 (95% CI À1.18 to À0.02). According to the predefined categories, the effect size was moderate and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate because of inconsistency.
For Forest Plots see Supporting Information Fig. S2. 3.4.3 CBTs versus recommended pharmacological therapy at the end of treatment 3.4.3.1 Primary outcomes. Pain relief of 50% or greater: No study reported this outcome. The numbers were calculated by an imputation method. We entered two studies with 216 participants into an analysis of pain relief of 50% or greater. There was no statistically significant difference between CBTs and controls (pvalue 0.68). Sixteen out of 108 (14.8%) participants in CBTs groups and 23 out of 108 (21.3%) in control groups reported pain relief of 50% or greater. RD was À0.05 (95% CI À0.29 to 0.19). The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Improvement of health-related quality of life of 20% or greater: We entered two studies with 216 participants into an analysis of improvement of health-related quality of life of 20% or greater. There was no statistically significant difference between CBTs and controls (p-value 0.07). Eighty out of 108 (74.1%) participants in CBTs groups and 40 out of 108 (37.0%) participants in control groups reported improvement of health-related quality of life of 20% or greater. RD was 0.38 (95% CI À0.04 to 0.80). The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Negative mood: We entered two studies with 216 participants into an analysis of reduction in negative mood. There was no statistically significant difference between CBTs and controls (p-value 0.23). SMD was À0.50 (95% CI À1.32 to 0.31). The quality of evidence was downgraded by two levels to lowquality evidence because of imprecision and inconsistency.
Disability: There was only one study available. Fatigue: There was only one study available. Acceptability: We entered two studies with 216 participants into an analysis of acceptability. There was no statistically significant difference between CBTs and controls (p-value 0.30). Six out of 108 (5.6%) participants in CBT-groups and 9 out of 108 (8.3%) in controls dropped out of the study due to any reason. RD was À0.03 (95% CI À0.09 to 0.03). The quality of evidence was downgraded by one level to moderate quality evidence because of imprecision.
Safety: There was only one study available.
3.4.3.2 Secondary outcomes. Pain relief of 30% or greater: We entered two studies with 216 participants into an analysis of pain relief of 30% or greater. There was no statistically significant difference between CBTs and controls (p-value 0.54). Sixty five out of 108 (60.2%) participants in CBTs groups and 53 out of 108 (49.1%) in control groups reported pain relief of 30% or greater. RD was 0.11 (95% CI À0.24 to 0.47). The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Mean pain intensity: We entered two studies with 217 participants into an analysis of reduction in mean pain. There was no statistically significant difference between CBTs and controls (p-value 0.29). SMD was À0.43 (95% CI À1.21 to 0.36. The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Coping with pain: We entered two studies with 216 participants into an analysis of improved coping with pain. There was a statistically significant difference between CBTs and controls (p-value < 0.0001). SMD was À1.13 (95% CI À1.54 to À0.72). According to the predefined categories, the effect size was large and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate quality evidence because of imprecision.
Sleep Improvement of health-related quality of life of 20% or greater: We entered two studies with 216 participants into an analysis of improvement of health-related quality of life of 20% or greater. There was no statistically significant difference between CBTs and controls (p-value 0.07). Seventy five out of 108 (69.4%) participants in CBTs groups and 36 out of 108 (33.3%) participants in control groups reported improvement of health-related quality of life of 20% or greater. RD was RD 0.37, 95% CI À0.07 to 0.81]. The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Negative mood: We entered two studies with 216 participants into an analysis of reduction in negative mood. There was no statistically significant difference between CBTs and controls (p-value 0.16). SMD was À0.42 (95% CI À1.00 to 0.17). The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Disability: There was only one study available. Fatigue: There was only one study available.
3.4.4.2 Secondary outcomes. Pain relief of 30% or greater: We entered two studies with 216 participants into an analysis of pain relief of 30% or greater. There was no statistically significant difference between CBTs and controls (p-value 0.74). Fifty six out of 108 (51.9%) participants in CBTs groups and 50 out of 108 (46.3%) in control groups reported pain relief of 30% or greater. RD was 0.06 (95% CI À0.29 to 0.41). The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Mean pain intensity: We entered two studies with 216 participants into an analysis of reduction in mean pain reduction. There was no statistically significant difference between CBTs and controls (p-value 0.35). SMD was À0.29 (95% CI À0.89 to 0.31). The quality of evidence was downgraded by two levels to low-quality evidence because of imprecision and inconsistency.
Coping with pain: We entered two studies with 216 participants into an analysis of improved coping with pain. CBTs were statistically significant superior to controls (p-value < 0.0001). SMD was À1.05 (95% CI À1.34 to À0.77). According to the predefined categories, the effect size was large and there was a clinically relevant benefit by CBTs. The quality of evidence was downgraded by one level to moderate quality evidence because of imprecision.
Sleep problems: Not reported. For Forest Plots see Supporting Information Fig. S4 .
Heterogeneity
There was considerable heterogeneity (I² > 75%) in the comparisons improvement of HRQOL of 20% or greater, mean pain intensity and coping with pain at the end of treatment, and in the comparisons improvement of HRQOL of 20% or greater, negative mood, disability, coping with pain and sleep problems at long-term follow-up. We assume methodological difference across studies for this considerable heterogeneity.
Publication bias
Studies with 325 participants with a null effect on improvement of health-related quality of life of 20% or greater would have been required to make the result clinically irrelevant (NNTB of 10 or higher).
Subgroup analyses
Different types of CBTs
End of treatment: There were no statistically significant overall subgroup differences in the outcomes 50% and more pain relief (p-value 0.52), negative mood (p-value 0.10), disability (p-value 0.59), acceptability (p-value 0.13), 30% and more pain relief (p-value 0.16), mean pain intensity reduction (p-value 0.07) and coping with pain (p-value 0.14). The test for overall subgroup differences was statistically significant for at least 20% improvement of HRQOL (p-value 0.03).
Long-term follow-up: Only traditional CBTs and operant therapy were compared. There was no statistically significant difference between both types of CBTs in pain relief 50% or greater (p-value 0.07) and reduction in mean pain intensity (p-value 0.06). Operant therapy was superior to traditional CBTs in improvement of HRQOL of 20% or greater (p-value 0.007), reduction in disability (p-value 0.008), of negative mood (p-value 0.005), in pain relief 30% or greater (p-value 0.009) and coping with pain (p-value 0.05).
Treatment duration
One study which did not report treatment duration (Woolfolk et al., 2012) was excluded from this analysis. Studies with >25 h (Wigers et al., 1996; Thieme et al., 2006; Falcao et al., 2008; Castel et al., 2012; Karlsson et al., 2015) and >50 h (Soares and Grossi, 2002; Thieme et al., 2003) were included in a group labelled 'long-term' CBTs. At end of treatment, the effect sizes of long-term CBTs on pain and disability were not statistically significant, the effect size on negative mood was moderate and statistically significant. At long-term followup, the effect sizes of long-term CBTs on negative mood and disability were large and statistically significant and on pain medium and statistically significant. The remaining studies with a study intensity of 5-25 h were included in a group labelled 'shortterm' CBTs. At end of treatment, the effect sizes of short-term CBTs on negative mood and disability were small and statistically significant, the effect size on pain was not statistically significant. At long-term follow-up, the effect sizes of short-term CBTs on negative mood and disability were not statistically significant. The effect size on pain was small and statistically significant (see Supporting Information Table S3 ).
Reported treatment quality
The effect sizes of CBTs with low reported treatment quality on pain, negative mood and disability at end of treatment were not statistically significant. The effect sizes of CBTs with moderate reported treatment quality on negative mood and disability at end of treatment were small and statistically significant, the effect size on pain was not statistically significant. The effect sizes of CBTs with high reported treatment quality on disability and pain at end of treatment were small and statistically significant, the effect size on mood at end of treatment was moderate and statistically significant (see Supporting Information Table S4 ).
Children and adolescents versus adults
The effect size of traditional CBT on mean pain intensity at end of treatment in children and adolescents was small and statistically significant. The effect sizes on negative mood and disability at end of treatment were not statistically significant. The effect sizes of traditional CBT on mean pain intensity, negative mood and disability in adults at end of treatment were small and statistically significant (see Supporting Information Table S5 ).
Sensitivity analyses
Removing studies with data substituted or extracted from figures did not change the magnitude and significance of the effect sizes of CBTs on pain, negative mood and disability at end of treatment. Removing studies with <20 participants per treatment arm did not change the magnitude and significance of the effect sizes of CBTs on pain, negative mood and disability at end of treatment (see Supporting Information Table S6 ).
Discussion
Summary of main results
CBTs were superior to controls (waiting list, attention control, treatment as usual, other active nonpharmacological therapies) in pain relief of 50% or greater, in improving of health-related quality of life of 20% or greater and in reducing negative mood and disability at the end of treatment and in pain relief of 50% or greater and in reducing negative mood and disability at long-term follow-up. CBTs were not superior to controls in improvement of health-related quality of life of 20% or greater at long-term follow-up.
Subgroup analyses demonstrated that a reduction in mean pain intensity, negative mood and disability were detectable for traditional CBTs and acceptancebased CBTs at end of treatment and at long-term follow-up and for operant therapy at follow-up, but not for operant therapy or self management education programs at end of treatment if compared to nonpharmacological controls.
CBTs did not differ in efficacy except superiority for coping with pain from recommended drug therapy (pregabalin and/or duloxetine) at the end of treatment and at long-term follow-up.
Overall completeness and applicability of evidence
The applicability (external validity) of evidence is strong for the following reasons.
(1) The studies were not only performed in university centres but also in primary and secondary care. (2) Patients with anxiety or depressive disorder, or both, which are frequently associated with FM, were included in most studies. (3) Subgroup analysis demonstrated the efficacy of CBTs in children and adolescents and in adults. However, the majority of the participants were middle-aged Caucasian women, making it difficult to apply the results to the total FM population, especially to male and non-Caucasian patients. No study performed a subgroup analysis for male and nonCaucasian patients.
CBTs approaches may be more acceptable and easier to implement in western populations whose cultures are 'individualist' (where individual self-realization is everything and relationships with family and others are subordinate), and less acceptable and more difficult to incorporate into daily lives in patients from 'collectivist' cultures (where networks, kinship and the roles they bring are very important and goals are pursued within those constraints) (Naeem et al., 2015) .
Potential biases in the review process
We cannot be certain that other studies that have not been published (with positive or negative results) were not identified. We might have underestimated the methodological and treatment quality of some studies which might not have reported some details required for the risk of bias and treatment quality scores used. We relied on the reported data for quality assessment and did not ask authors for further details because we did not want to introduce a 'response' bias. We have experienced in previous reviews on psychological therapies that it was impossible to get any details, on request, of studies conducted before 2005 . Even some authors of studies conducted after 2010 did not respond to our requests for outcomes not reported for this review. We had to calculate missing values by established imputation methods and to extract data from figures, for one study each. However, excluding these studies from analyses did not change the significance and magnitude of the effect sizes.
Agreements with other reviews
The conclusions of our previous review of the efficacy of (traditional, operant) CBTs to reduce some key symptoms and disability in FMS remain unchanged and concur with the ones of a recent overveiw of systematic reviews of CBTs in FMS (K€ ollner et al., 2017) . Our updated review could include three studies with acceptance-based approaches. Our results are in line with a recent systematic review which demonstrated that acceptance and commitment therapy is superior to controls (no therapy, therapy as usual) in pain acceptance and in reducing negative mood (Hughes et al., 2017) . The results of our comparison of CBTs versus best recommended pharmacological drug therapy is in accordance with the results of a network meta-analysis which found no differences in the efficacy of CBTs compared to some antidepressants and convulsants in reducing pain and improving HRQOL (N€ uesch et al., 2015) .
Implications for clinical practice
Traditional cognitive behavioural therapy, acceptance-based cognitive therapies and operant therapy between 5 and 25 h reduce some key symptoms of fibromyalgia after 6 months. More intensive therapies (up to 75 h) might improve long-term outcomes. Evidence was not found for benefit of self management programmes as single therapy. In some countries (for example USA), CBTs might not be easily available for patients and might be expensive and not covered by health insurance.
Implications for research
See Supporting Information Discussion S1 and Data S1.
Major tasks for future research
• The definition of subgroups (e.g. FMS patients with and without major depression or post-traumatic stress disorder, pain persistence and pain avoidance behaviour) with development of more tailored therapies to these subgroups.
• The identification of common (e.g. therapeutic relationship) and specific (e.g. psychological flexibility, inhibitory learning or acceptance) treatment mechanisms by more frequent measures than prepost assessment allowing examination of lagged relationships over time.
• The identification of predictors of a favourable outcome such as demographic (e.g. age, education) and clinical (e.g. disease severity, treatment expectations) variables by moderator analyses.
• The comparison of face-to-face versus telephone or Internet-based therapies in terms of efficacy, acceptability and costs.
• The comparison of combined therapies (e.g. CBTs plus a drug) versus single therapy (e.g. CBTs or drug alone) in terms of efficacy, safety and costs.
• The comparison of traditional versus acceptancebased CBTs in terms of efficacy and acceptability.
• The development of graduated treatment approaches (e.g. education, standard CBTs, multicomponent therapies) depending on the severity of fibromyalgia; and
• The application of new study designs beyond the 'gold standard' of RCTs, e.g. clinical effectiveness trials. In 2013, the Cochrane authors Eccleston et al. argued that there should be a halt on trial registration, until the quality and focus of studies with CBTs in chronic pain radically improve, because of a significant threat of research waste. Our analyses of the methodology problems of most of the studies analysed in this review supports their postulation, that there should be no new trials until these critical problems are addressed (Eccleston and Crombez, 2017) .
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